Welcome to our dedicated page for Medtronic news (Ticker: MDT), a resource for investors and traders seeking the latest updates and insights on Medtronic stock.
Medtronic plc (NYSE: MDT) is a Galway, Ireland-based healthcare technology company whose news flow reflects its broad activity in medical devices, diabetes technology, surgical robotics, and cardiovascular therapies. Company announcements frequently highlight regulatory milestones, clinical evidence, product launches, capital markets activity, and corporate governance developments that matter to investors and healthcare professionals following MDT stock.
Recent news has featured U.S. Food and Drug Administration clearances for key technologies, including the Hugo robotic-assisted surgery (RAS) system for urologic procedures and the MiniMed Go Smart Multiple Daily Injection (MDI) system, which connects the InPen smart insulin pen and the Instinct sensor made by Abbott through the MiniMed Go app. Medtronic has also reported on the broad U.S. commercial launch of the MiniMed 780G automated insulin delivery system integrated with the Instinct sensor, expanding its diabetes technology ecosystem.
Investors can also track Medtronic’s cardiovascular and hypertension-related developments, such as the final National Coverage Determination from the U.S. Centers for Medicare & Medicaid Services for the Symplicity Spyral renal denervation system, and updates on growth drivers like pulsed field ablation and other cardiovascular therapies discussed in earnings releases. Financial news includes quarterly earnings reports, guidance updates, dividend declarations, and details of senior notes offerings and redemptions.
This MDT news page aggregates coverage of topics including diabetes business developments (such as the planned MiniMed IPO registration), conference presentations, leadership and board changes, and major clinical or reimbursement milestones. Readers interested in Medtronic’s role in chronic disease management, minimally invasive surgery, and global healthcare technology can use this page to follow ongoing announcements and review the company’s evolving strategic priorities over time.
Medtronic (NYSE:MDT) has launched ELEVATE-HFpEF, a global pivotal study investigating a novel cardiac pacing treatment for patients with Heart Failure with preserved Ejection Fraction (HFpEF). The study will evaluate whether personalized elevated pacing rates using conduction system pacing can improve outcomes for HFpEF patients.
The trial will enroll up to 700 participants across multiple regions, using Medtronic's commercially available pacemaker and SelectSecure™ MRI SureScan™ Model 3830 pacing leads. The study targets HFpEF, which affects 32 million people worldwide and represents approximately 50% of heart failure cases. Participants will be followed for one year to assess the efficacy and safety of this investigative treatment.
Medtronic (NYSE:MDT) announced positive results from the Enable Hernia Repair clinical study evaluating their Hugo™ robotic-assisted surgery (RAS) system. The study, involving 193 patients, is the first-ever IDE clinical study for robotic-assisted hernia surgery in the U.S.
The study achieved remarkable results, with a 100% surgical success rate, exceeding the 85% performance goal. Safety endpoints were met with a 0.0% surgical site event rate for inguinal repairs and 2.1% for ventral repairs, both significantly below the 30% threshold. Mean hospital stays were brief at 4.7 hours for inguinal and 6.7 hours for ventral procedures.
The Hugo RAS system is currently available in 30+ countries across five continents, with FDA review ongoing for urology indication and planned expansions into hernia repair and gynecology.
Medtronic (NYSE:MDT) announced two significant FDA milestones for its MiniMed™ 780G system: clearance of the SmartGuard™ algorithm for integration with Abbott's Instinct sensor in type 1 diabetes, and approval for use in adults with type 2 diabetes.
The integration with Abbott's Instinct sensor, the world's smallest and thinnest integrated CGM with a 15-day wear time, will be available after compliance documentation completion. In clinical trials for type 2 diabetes patients, the system demonstrated impressive results, including a 0.7% reduction in HbA1c and increased Time in Range to 81% from 72%.
The MiniMed™ 780G becomes the first and only automated insulin delivery system with Meal Detection™ technology available for type 2 diabetes patients, marking a significant advancement in diabetes management technology.
Medtronic plc (NYSE:MDT), a global healthcare technology leader, has announced its participation in four major investor conferences in September 2025. Key executives, including Chairman and CEO Geoff Martha and CFO Thierry Piéton, will represent the company at the Wells Fargo Healthcare Conference, Morgan Stanley Global Healthcare Conference, Deutsche Bank Healthcare Summit, and BofA Global Research Healthcare Conference.
The company, headquartered in Galway, Ireland, serves over 150 countries with a team of 95,000+ employees. Medtronic's technologies address 70 health conditions, including cardiac devices, surgical robotics, insulin pumps, and patient monitoring systems. Live webcasts of all conference sessions will be available through the company's investor relations website.
Medtronic (NYSE:MDT) has announced significant governance changes and strategic initiatives aimed at enhancing shareholder value. The company has appointed two new independent directors to its Board: John Groetelaars and Bill Jellison, both bringing extensive medical technology industry experience.
The Board has established two new special committees: a Growth Committee focusing on M&A, R&D investments, and potential divestitures (including the planned Diabetes business separation), and an Operating Committee dedicated to optimizing operational performance and margin expansion. These initiatives follow constructive engagement with Elliott Investment Management, one of Medtronic's largest investors.
The company plans to host an Investor Day in mid-2026 to discuss strategic priorities and financial objectives.
Medtronic (NYSE:MDT) reported strong Q1 FY2026 results with revenue reaching $8.6 billion, an 8.4% increase as reported and 4.8% organic growth. The company achieved GAAP diluted EPS of $0.81 (up 1%) and non-GAAP diluted EPS of $1.26 (up 2%).
Key performance highlights include Cardiac Ablation Solutions revenue surge of nearly 50% (72% in US) driven by pulsed field ablation products. The Cardiovascular Portfolio led growth with a 7.0% organic increase, while the Diabetes business showed strong performance with 7.9% organic growth.
Looking ahead, Medtronic raised its FY26 EPS guidance to $5.60-$5.66 (previously $5.50-$5.60) while maintaining organic revenue growth guidance of approximately 5%. The company expects reduced tariff impact of approximately $185 million, down from the previous estimate of $200-350 million.
Medtronic (NYSE:MDT) has declared a quarterly cash dividend of $0.71 per ordinary share for the second quarter of fiscal year 2026. The dividend will be paid on October 17, 2025, to shareholders of record as of September 26, 2025.
This declaration maintains the dividend level announced in May 2025. As a member of the S&P 500 Dividend Aristocrats index, Medtronic has consistently increased its annual dividend for 48 consecutive years. The company operates globally with 95,000+ employees across 150+ countries, focusing on healthcare technology solutions that address 70 different health conditions.
Medtronic (NYSE:MDT), the global healthcare technology leader, has scheduled its fiscal year 2026 first quarter financial results announcement for Tuesday, August 19, 2025. The results will cover the period ending July 25, 2025.
The company will release its financial summary at 5:45 a.m. CDT, followed by a video webcast at 7:00 a.m. CDT. Medtronic has also announced the reporting dates for the remaining quarters of FY2026: November 18, 2025 (Q2), February 17, 2026 (Q3), and May 20, 2026 (Q4).
Medtronic (NYSE:MDT) has secured CE Mark approval for expanded indications of its MiniMed™ 780G system, now authorized for use in children as young as 2 years old, pregnant women, and type 2 diabetes patients in Europe.
Clinical data showed significant benefits across all new indications: The LENNY trial demonstrated a 0.6% lower HbA1C and 9.9% higher time in range in children aged 2-6 years. For pregnant women, the system achieved an average Pregnancy Time in Range of 66.5%. In type 2 diabetes patients, trials showed a 0.7% reduction in HbA1c and increased time in range to 80%.
The company is currently seeking FDA approval for type 2 diabetes indication in the U.S. and conducting clinical trials for use in young children.
Medtronic (NYSE:MDT) has appointed Chad Spooner as Chief Financial Officer of MiniMed, effective July 14, 2025, ahead of its planned separation into an independent public company. Spooner brings over 25 years of financial leadership experience, most recently serving as CFO at BIC.
The appointment comes as Medtronic prepares to spin off its diabetes business under the MiniMed name within 18 months of the initial announcement. MiniMed focuses on transforming diabetes care for patients with type 1 and type 2 diabetes requiring daily insulin injections. The separation will be executed through a series of capital markets transactions, subject to customary conditions and legal requirements.